… The EGFR-TKIs investigated in this study were gefitinib and erlotinib. Afatinib had not yet
been approved by NHI during the study period. The prescription duration of individual EGFR-…

… As mentioned above, both randomized controlled trials and cohort studies were included in
… bias in cohort studies, with emphasis on comparability between gefitinib and erlotinib groups …

… Such an uneven distribution of squamous cell carcinoma may interfere with the observation
of the efficacy of erlotinib in the entire study cohort. However, no differences in OS or TTF …

… A retrospective cohort study of 88 NSCLC patients with EGFR mutation positive treated
with gefitinib (n=59), erlotinib (n=22), and afatinib (n=7) was performed in national cancer …

… This is the first large cohort study of real-world performance of first-line gefitinib, erlotinib
and afatinib chosen by clinicians in a freely competitive manner. This is also the first report to …

… This is a retrospective study of a prospectively maintained cohort. The aims of this study were
to compare the efficacy among three first-generation EGFR-TKIs as adjuvant treatment and …

… 17.3 months for gefitinib, 12.4 months for erlotinib, and 23.3 … –0.83) compared with gefitinib
or erlotinib. In the competing … failure compared with gefitinib or erlotinib after adjusting for both …

… every 21 days), or gefitinib (250 mg orally daily). Erlotinib and gefitinib were given to patients
… the start of treatment with the study drug (docetaxel, erlotinib, or gefitinib). Response was …

… A retrospective cohort study of Chinese patients with metastatic NSCLC harboring EGFR
mutations who received first-line gefitinib, erlotinib or afatinib treatment, followed by osimertinib …

… However, Chiu et al. reported gefitinib and erlotinib were … No study has compared these two
generations of EGFR-TKIs … retrospective study to assess the efficacy of gefitinib/erlotinib and …